

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7385754

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
Name		Execution Date
TRILLIUM THERAPEUTICS ULC		04/21/2022
RECEIVING PARTY DATA		
Name:	PF ARGENTUM IP HOLDINGS LLC	
Street Address:	235 EAST 42ND STREET	
City:	NEW YORK	
State/Country:	NEW YORK	
Postal Code:	10017	
PROPERTY NUMBERS Total: 17		
Property Type	Number	
Patent Number:	9969789	
Patent Number:	10906954	
Application Number:	16092168	
Application Number:	16344985	
Application Number:	16344974	
Application Number:	16496168	
Application Number:	16759981	
Application Number:	16979707	
Application Number:	16979754	
Application Number:	17272413	
Application Number:	17297353	
Application Number:	63180604	
Application Number:	63219207	
Application Number:	63253125	
Application Number:	63273851	
Application Number:	63277101	
Application Number:	17133489	
CORRESPONDENCE DATA		
Fax Number:	(860)686-6244	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent</i>		
PATENT		

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: janice.m.denison@pfizer.com
Correspondent Name: PFIZER INC.
Address Line 1: 235 EAST 42ND STREET
Address Line 2: ATTN: LEGAL PATENT DEPARTMENT, CHIEF IP COUNSEL
Address Line 4: NEW YORK, NEW YORK 10017

ATTORNEY DOCKET NUMBER:	TRILLIUM-PFARGENTUM APPS
--------------------------------	--------------------------

NAME OF SUBMITTER:	JANICE DENISON
---------------------------	----------------

SIGNATURE:	/Janice Denison/
-------------------	------------------

DATE SIGNED:	06/16/2022
---------------------	------------

Total Attachments: 6

source=2022 April Assignment (Trillium to PF Argentum) 4.21.2022 (002)#page1.tif
source=2022 April Assignment (Trillium to PF Argentum) 4.21.2022 (002)#page2.tif
source=2022 April Assignment (Trillium to PF Argentum) 4.21.2022 (002)#page3.tif
source=2022 April Assignment (Trillium to PF Argentum) 4.21.2022 (002)#page4.tif
source=2022 April Assignment (Trillium to PF Argentum) 4.21.2022 (002)#page5.tif
source=2022 April Assignment (Trillium to PF Argentum) 4.21.2022 (002)#page6.tif

ASSIGNMENT / CONFIRMATORY ASSIGNMENT

For valuable consideration, the receipt and adequacy of which is hereby acknowledged, Trillium Therapeutics Inc. (converted to "Trillium Therapeutics ULC" on November 20, 2021) ("Assignor"), a company organized and existing under the laws of Canada, having its principal place of business at 2488 Dunwin Drive, Mississauga, Ontario L5L 1J9/CA, hereby confirm the assignment and transfer unto PF Argentum IP Holdings LLC ("Assignee"), a limited liability company organized and existing under the laws of the State of Delaware, United States of America, and having its principal place of business at, 235 East 42nd Street, New York, New York 10017 its entire right, title, and interest in and to any patent application or patent listed in the Schedule A attached hereto and expressly made a part hereof; its entire right, title and interest, in all countries of the world as disclosed in the patent applications and patents listed in the Schedule A; its entire right, title and interest in and to all continuations, divisions, continuations-in-part, reissues, reexaminations and extensions thereof; its entire right, title, and interest in and to all patent applications and patents in all countries of the world claiming priority from the patent applications and patents listed in the Schedule A, its entire right, title, and interest, if any, in and to all patent applications and patents in all countries of the world from which the patent applications and patents listed in the Schedule A claim priority, and the right to claim priority from any such patent application or patent under the Paris Convention for the Protection of Industrial Property, and under any and all other such treaties and agreements to which the United States of America is a party and which afford similar priority-claiming privileges, in all countries of the world; as well as the right to sue in the name of Assignor and recover damages for past infringement of any patent application or patent assigned hereby;

And Assignor hereby confirms the agreement, whenever requested, to communicate to said Assignee and its successors and assigns, any facts known to it respecting said inventions, to testify in any legal proceeding respecting said inventions, and to execute all applications or papers necessary to obtain and maintain proper patent protection on said inventions in all countries of the world;

And Assignor confirms the authorization of Assignee or its designee to supply any missing patent application or patent identification information or correct any errors in the patent

Assignment / Confirmatory Assignment
Trillium Therapeutics Inc. to PF Argentum IP Holdings LLC

application or patent identification information provided herein whether discovered prior to or after recordation;


And Assignor hereby confirms the appointment of Assignee, through its designee, its attorney-in-fact to execute, in its name and on its behalf, any and all documents required to effectuate this Assignment, including but not limited to further assignments, corrective assignments, powers of attorney and other papers.

This confirmatory assignment is made pursuant to and in compliance with the Business Transfer Agreement signed between Trillium Therapeutics Inc. and PF Argentum IP Holdings LLC, made effective as of 18 November, 2021.

Signed and witnessed this 21st day of April 2022, at New York, New York, USA

Assignor: Trillium Therapeutics ULC (formerly Trillium
Therapeutics Inc. until November 20, 2021)

By:



Name: Andrew J. Muratore

Title: Director and Vice President



Witness Signature

Owen S. Muratore

Name

145 East 84th St., NY, NY

Mailing Address


(646) 505-9716

Phone or email

Signed and witnessed this 21 day of April 2022, at New York, New York, USA


Assignee: PF Argentum IP Holdings LLC

By:



Name: Andrew Muratore

Title: Vice President



Witness Signature

Owen Muratore

Name

145 E 84th St. NY, NY 10078

Mailing Address

646 505 9716

Phone or email

Schedule A

<u>Country</u>	<u>Application Number</u>	<u>Application Date</u>	<u>Patent Number</u>	<u>Grant Date</u>
Albania	13865442.1	12/17/2013	2931752	8/13/2019
Australia	2020202119	12/17/2013		
Australia	2013362789	12/17/2013	2013362789	3/8/2018
Australia	2017250029	4/13/2017	2017250029	3/17/2022
Australia	2019235626	3/8/2019		
Australia	2019235627	3/8/2019		
Australia	2019336345	8/29/2019		
Australia	2021261886	11/3/2021		
Austria	13865442.1	12/17/2013	2931752	8/13/2019
Austria	19185175.7	7/9/2019	3575326	4/13/2022
Belgium	13865442.1	12/17/2013	2931752	8/13/2019
Belgium	19185175.7	7/9/2019	3575326	4/13/2022
Bosnia-Herzegovina	13865442.1	12/17/2013	2931752	8/13/2019
Bulgaria	13865442.1	12/17/2013	2931752	8/13/2019
Bulgaria	19185175.7	7/9/2019	3575326	4/13/2022
Canada	2894245	12/17/2013	2894245	3/22/2022
Canada	3020026	4/13/2017		
Canada	3042583	11/1/2017		
Canada	3042581	11/1/2017		
Canada	3057718	3/27/2018		
Canada	3080640	11/5/2018		
Canada	3093603	3/8/2019		
Canada	3093549	3/8/2019		
Canada	3111323	8/29/2019		
Canada	3121273	11/28/2019		
Canada	3145468	1/11/2022		
China	201380073010	12/17/2013	105073780	4/12/2019
China	201910261473X	12/17/2013		
China	201780032979.2	4/13/2017		
China	201880035184.1	3/27/2018		
China	2019800186868	3/8/2019		
China	2019800213723	3/8/2019		
China	2019800619239	8/29/2019		
Croatia	13865442.1	12/17/2013	2931752	8/13/2019
Cyprus	13865442.1	12/17/2013	2931752	8/13/2019
Czech Republic	13865442.1	12/17/2013	2931752	8/13/2019
Czech Republic	19185175.7	7/9/2019	3575326	4/13/2022
Denmark	13865442.1	12/17/2013	2931752	8/13/2019
Denmark	19185175.7	7/9/2019	3575326	4/13/2022
Estonia	13865442.1	12/17/2013	2931752	8/13/2019
European Patent Convention	13865442.1	12/17/2013	2931752	8/13/2019
European Patent Convention	17781686.5	4/13/2017		
European Patent Convention	17868258.9	11/1/2017		
European Patent Convention	17868118.5	11/1/2017		

Assignment / Confirmatory Assignment
Trillium Therapeutics Inc. to PF Argentum IP Holdings LLC

European Patent Convention	18774883.5	3/27/2018		
European Patent Convention	18874304.1	11/5/2018		
European Patent Convention	19767311.4	3/8/2019		
European Patent Convention	19767604.2	3/8/2019		
European Patent Convention	19185175.7	7/9/2019	3575326	4/13/2022
<u>Country</u>	<u>Application Number</u>	<u>Application Date</u>	<u>Patent Number</u>	<u>Grant Date</u>
European Patent Convention	19888505.5	11/28/2019		
European Patent Convention	22162692.2	3/17/2022		
Finland	13865442.1	12/17/2013	2931752	8/13/2019
Finland	19185175.7	7/9/2019	3575326	4/13/2022
France	13865442.1	12/17/2013	2931752	8/13/2019
France	19185175.7	7/9/2019	3575326	4/13/2022
Germany	13865442.1	12/17/2013	2931752	8/13/2019
Germany	19185175.7	7/9/2019	3575326	4/13/2022
Great Britain	13865442.1	12/17/2013	2931752	8/13/2019
Great Britain	19185175.7	7/9/2019	3575326	4/13/2022
Greece	13865442.1	12/17/2013	2931752	8/13/2019
Greece	19185175.7	7/9/2019	3575326	4/13/2022
HK - (Hong Kong)	16105678.0	5/18/2016	1217716	5/22/2020
HK - (Hong Kong)	62021034602.4	3/8/2019		
HK - (Hong Kong)	62021034603.2	3/8/2019		
HK - (Hong Kong)	42020005406.2	4/7/2020		
HK - (Hong Kong)	62020013220.2	8/5/2020		
HK - (Hong Kong)	62020013220.2	8/5/2020		
HK - (Hong Kong)	62021027193.2	3/15/2021		
HK - (Hong Kong)	62022046078.1	1/12/2022		
Hungary	13865442.1	12/17/2013	2931752	8/13/2019
Hungary	19185175.7	7/9/2019	3575326	4/13/2022
Iceland	13865442.1	12/17/2013	2931752	8/13/2019
Iceland	19185175.7	7/9/2019	3575326	4/13/2022
India	5935/DELNP/2015	12/17/2013	391505	3/9/2022
India	201817041449A	4/13/2017		
India	202018032384	7/28/2020		
Ireland	13865442.1	12/17/2013	2931752	8/13/2019
Ireland	19185175.7	7/9/2019	3575326	4/13/2022
Italy	13865442.1	12/17/2013	2931752	8/13/2019
Italy	19185175.7	7/9/2019	3575326	4/13/2022
Japan	2015-548121	12/17/2013	6335189	5/30/2018
Japan	2018-084885	12/17/2013	6664430	2/20/2020
Japan	2018-554325	4/13/2017		
Japan	2020-547336	3/8/2019		
Japan	2020-547197	3/8/2019		
Japan	2021-536117	8/29/2019		
Japan	2020-023936	2/17/2020		
Latvia	13865442.1	12/17/2013	2931752	8/13/2019
Lithuania	13865442.1	12/17/2013	2931752	8/13/2019
Luxembourg	13865442.1	12/17/2013	2931752	8/13/2019
Luxembourg	19185175.7	7/9/2019	3575326	4/13/2022
Macedonia	13865442.1	12/17/2013	2931752	8/13/2019
Malta	13865442.1	12/17/2013	2931752	8/13/2019

Assignment / Confirmatory Assignment
Trillium Therapeutics Inc. to PF Argentum IP Holdings LLC

Monaco	13865442.1	12/17/2013	2931752	8/13/2019
Montenegro	13865442.1	12/17/2013	2931752	8/13/2019
Netherlands	13865442.1	12/17/2013	2931752	8/13/2019
Netherlands	19185175.7	7/9/2019	3575326	4/13/2022
Norway	13865442.1	12/17/2013	2931752	8/13/2019
<u>Country</u>	<u>Application Number</u>	<u>Application Date</u>	<u>Patent Number</u>	<u>Grant Date</u>
Poland	13865442.1	12/17/2013	2931752	8/13/2019
Poland	19185175.7	7/9/2019	3575326	4/13/2022
Portugal	13865442.1	12/17/2013	2931752	8/13/2019
Portugal	19185175.7	7/9/2019	3575326	4/13/2022
Romania	13865442.1	12/17/2013	2931752	8/13/2019
Romania	19185175.7	7/9/2019	3575326	4/13/2022
San Marino	13865442.1	12/17/2013	2931752	8/13/2019
Serbia	13865442.1	12/17/2013	2931752	8/13/2019
Slovak Republic	13865442.1	12/17/2013	2931752	8/13/2019
Slovak Republic	19185175.7	7/9/2019	3575326	4/13/2022
Slovenia	13865442.1	12/17/2013	2931752	8/13/2019
Slovenia	19185175.7	7/9/2019	3575326	4/13/2022
Spain	13865442.1	12/17/2013	2931752	8/13/2019
Spain	19185175.7	7/9/2019	3575326	4/13/2022
Sweden	13865442.1	12/17/2013	2931752	8/13/2019
Sweden	19185175.7	7/9/2019	3575326	4/13/2022
Switzerland	13865442.1	12/17/2013	2931752	8/13/2019
Switzerland	19185175.7	7/9/2019	3575326	4/13/2022
Turkey	13865442.1	12/17/2013	2931752	8/13/2019
Turkey	19185175.7	7/9/2019	3575326	4/13/2022
United States of America	14/653165	12/17/2013	9969789	5/15/2018
United States of America	16/092168	4/13/2017		
United States of America	16/344985	11/1/2017		
United States of America	16/344974	11/1/2017		
United States of America	16/496168	3/27/2018		
United States of America	15/962540	4/25/2018	10906954	2/2/2021
United States of America	16/759981	11/5/2018		
United States of America	16/979707	3/8/2019		
United States of America	16/979754	3/8/2019		
United States of America	17/272413	8/29/2019		
United States of America	17/297353	11/28/2019		
United States of America	17/133489	12/23/2020		
United States of America	63/180604	4/27/2021		
United States of America	63/219207	7/7/2021		
United States of America	63/253125	10/6/2021		
United States of America	63/273851	10/29/2021		
United States of America	63/277101	11/8/2021		